Veronica Novotny‐Diermayr

Author

Also Known As

V Novotny-Diermayr, V. Novotny-Diermayr, Veronica Novotny-Diermayr, Veronica Novotny‐Diermayr, Veronica Veronica Novotny-Diermayr

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Institute of Molecular and Cell Biology Experimental Drug Development Centre Agency for Science, Technology and Research National University of Singapore National University Cancer Institute, Singapore

About

Veronica Novotny‐Diermayr is an author at Institute of Molecular and Cell Biology specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	629
2	Cell Biology	4	4	304
3	Immunology	3	3	332
4	Biochemistry	1	1	132
5	Cellular Physiology	1	1	29

Veronica Novotny‐Diermayr

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies Stefan Hart, K C Goh, Veronica Novotny‐Diermayr, Leukemia	2011	195
SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer Veronica Novotny‐Diermayr, Kanda Sangthongpitag, Chang Hu, Molecular Cancer Therapeutics Liquid TumorsHigh Tumor ExposureOncologyBiochemistryMedicine	2010	132
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties K C Goh, Veronica Novotny‐Diermayr, Stefan Hart, Leukemia MedicineReceptor Tyrosine KinaseMalignant Blood DisorderImmunologyPotent Anti-leukemic Properties	2011	128
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia Stefan Hart, K. C. Goh, Veronica Novotny‐Diermayr, Blood Cancer Journal ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2011	106
A Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation Jing Ma, Tong Zhang, Veronica Novotny‐Diermayr, Journal of Biological Chemistry	2003	105
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML Veronica Novotny‐Diermayr, Stefan Hart, K C Goh, Blood Cancer Journal Mixed-phenotype Acute LeukemiaImmunologyCell DeathPharmacotherapyTumor Biology	2012	98
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy Nicholas C. DeVito, Michael Sturdivant, Balamayooran Thievanthiran, Cell Reports	2021	78
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer Stefan Hart, Veronica Novotny‐Diermayr, Kee Chuan Goh, Molecular Cancer Therapeutics Cancer BiologyTumor BiologyMolecular PharmacologyOncologyPi3k/mtor Pathway	2012	71
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers Jenny G. Low, Lawrence Lee, Eng Eong Ooi, Vaccine	2014	68
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours A.R. Abdul Razak, Sébastien J. Hotte, Lillian L. Siu, British Journal of Cancer	2011	63

Page 1